United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rapidscan pharma solutions eu ltd - regadenoson - solution for injection - 80microgram/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 75mg - injection with diluent - 75 mg - active: omalizumab 75mg excipient: histidine histidine hydrochloride polysorbate 20 sucrose water for injection - xolair is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige > 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled iwth inhaled corticosteroids.

Israel - English - Ministry of Health

rafa laboratories ltd - midazolam - solution for injection - midazolam 1 mg/ml - midazolam - midazolam - midazolam is a short-acting sleep-inducing drug that is indicated:in adults• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia- induction of anaesthesia- as a sedative component in combined anaesthesia• sedation in intensive care unitsin children• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia• sedation in intensive care units

Israel - English - Ministry of Health

rafa laboratories ltd - midazolam - solution for injection - midazolam 5 mg/ml - midazolam - midazolam - midazolam is a short-acting sleep-inducing drug that is indicated:in adults• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia- induction of anaesthesia- as a sedative component in combined anaesthesia• sedation in intensive care unitsin children• conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia• anaesthesia- premedication before induction of anaesthesia• sedation in intensive care units

Israel - English - Ministry of Health

novartis israel ltd - omalizumab - powder and solvent for solution for injection - omalizumab 150 mg/dose - omalizumab - omalizumab - allergic asthma xolair is indicated for patients 6 to 12 years of age with severe persistent asthma and for patients 12 years of age and older with moderate to severe persistent asthma, who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. limitations of use: xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. xolair is not indicated for the treatment of other allergic conditions.chronic rhinosinusitis with nasal polyps (crswnp) xolair is indicated as an add-on therapy with intranasal corticosteroids (inc) for the treatment of adults (18 years and above) with severe crswnp for whom therapy with inc does not provide adequate disease control.chronic spontaneous urticaria (csu) xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to h1 antihistamine treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150mg - powder for injection with diluent - 150 mg - active: omalizumab 150mg excipient: histidine histidine hydrochloride polysorbate 20 sucrose water for injection - xolair is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige > 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled iwth inhaled corticosteroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150 mg/ml - solution for injection - 150 mg/ml - active: omalizumab 150 mg/ml excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate polysorbate 20 water for injection - xolair (omalizumab) is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige greater than or equal to 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - omalizumab 150 mg/ml - solution for injection - 75 mg/0.5ml - active: omalizumab 150 mg/ml excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate polysorbate 20 water for injection - xolair (omalizumab) is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have ige greater than or equal to 30 iu/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - aminophylline - solution for injection - aminophylline 250 mg / 10 ml - aminophylline - aminophylline - for symptomatic relief or prevention of bronchial asthma and for treatment of reversible bronchospasm associated with chronic bronchitis and emphysema.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - diazepam - solution for injection - diazepam 10 mg / 2 ml - diazepam - diazepam - symptomatic relief of tension and anxiety either alone or when associated with stressful situations. psychoneurotic states manifested by tension, anxiety, apprehension, fatigue and depressive symptoms. in acute alcohol withdrawal, assival may be useful in the symptomatic relief of tremor, impending or acute delirium tremens and hallucinosis. assival is a useful adjunct in the relief of skeletal muscle spasm, spasticity, stiffman syndrome and tetanus. when used intravenously, assival injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. as premedication in patients undergoing surgical procedures (the intramuscular route is preferred) or in patients undergoing cardioversion (when the intravenous route is preferred).